HealthQuill USFDA
Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.
Drugs Health Pharma

Cassava’s disputed Alzheimer’s drug flops in end-stage trials

Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.

Read More
Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood cancer therapy.
Drugs Health Pharma

J&J seeks approval for its blood cancer therapy in US, European Union

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.

Read More
The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a new target date set for March next year.
Drugs Health Pharma

USFDA postpones Organon’s eczema drug review by three months

The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a.

Read More
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.
Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

Read More
Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the US regulator after a volunteer developed a serious nerve disorder.
Drugs Medical Pharma

USFDA puts on hold influenza, Covid-19 trial vaccines of Novavax

Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the.

Read More
Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder in haemophilia patients.
Drugs Health Pharma

Pfizer’s drug to treat rare haemophilia disorder gets US regulator’s approval

Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder.

Read More
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Drugs Health Pharma

Regeneron-Sanofi’s drug for lung disease gets US approval

Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.

Read More
IntraBio Inc, a biotechnology company focused on rare and neurodegenerative diseases, got the US regulator’s nod for a drug to treat a certain type of Niemann-Pick disease in adults and pediatric patients weighing about 15 kilograms.
Drugs Health Pharma

IntraBio Inc.’s drug for neurogenerative disorder gets US regulator’s nod

IntraBio Inc, a biotechnology company focused on rare and neurogenerative diseases, got the US regulator’s nod for a drug to treat a certain.

Read More
AstraZeneca’s Flumist, the first at-home flu vaccine, got approved by the Food and Drug Administration, enabling consumers with a prescription to order online beginning next year.
Drugs Medical Pharma

US drug regulator approves first nasal spray to prevent influenza

HQ Team September 22, 2024: AstraZeneca’s Flumist, the first at-home flu vaccine, got approved by the Food and Drug Administration, enabling consumers with.

Read More
The US Food and Drug Administration cleared Novavax’s Covid-19 vaccine, targeting the JN.1 strain, for people 12 years of age and older, according to a statement from the regulator.
Drugs Health Pharma

Novavax’s vaccine targeting JN.1 strain of Covid-19 virus gets FDA approval 

The US Food and Drug Administration cleared Novavax’s Covid-19 vaccine, targeting the JN.1 strain, for people 12 years of age and older, according.

Read More